Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer

Next Previous
Trial Profile

Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TOPARP; TOPARP-A; TOPARP-B

Most Recent Events

  • 10 Apr 2021 Results of exploratory analysis investigating the predictive value of an HRR function assay detecting RAD51 foci by immunofluorescence in tumor biopsies presented at the 112th Annual Meeting of the American Association for Cancer Research
  • 02 Dec 2019 Results presented in The Institute of Cancer Research Media Release.
  • 02 Dec 2019 According to The Institute of Cancer Research media release, this trial was funded in part by olaparib's manufacturer, AstraZeneca, plus by Cancer Research UK, Prostate Cancer UK, the Prostate Cancer Foundation, Movember and the Experimental Cancer Medicine Centre (ECMC) Network.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top